Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers

Andrea Necchi
Associate Professor, Vita-Salute San Raffaele UniversityHead of Genitourinary Medical OncologyIRCCS San Raffaele Hospital and Scientific InstituteVia Olgettina 60, 20132Milan, Italy
Philippe E. SpiessSenior Member, Department of GU OncologySenior Member, Department of Tumor BiologyAssistant Chief of Surgical ServicesMoffitt Cancer CenterProfessor, Department of UrologyUniversity of South FloridaTampa, FloridaUSA

Introduction.- State-of-the art and ongoing developments.- Clinical cases debate: neoadjuvant checkpoint inhibition vs standard chemotherapy.- Slideshow of tumor samples before and after checkpoint inhibition.- Ongoing trials and clinical trials endpoints debate: the role of pathological response as a surrogate of survival endpoints.- State-of-the-art and future role of molecular biomarkers for patient selection.- Background of immunotherapy trials in prostate cancer.- Clinical case debate: immunotherapy vs alternative therapies in the neoadjuvant and adjuvant setting of localized, high-risk prostate cancer.- Cytoreductive nephrectomy in the era of targeted therapy and immunotherapy.- Clinical cases debate: Neoadjuvant vs adjuvant immunotherapy in localized RCC.- Benchmark of surgical safety results.- What the scientific data tell us  about predictive biomarkers of immunotherapy efficacy across the GU malignancies.- Clinical cases debate: biomarker-driven patient selection vs unselective perioperative strategies.